SMET12

SMET12 is a bispecific antibody and T-cell engager (TCE) that targets both the human epidermal growth factor receptor (EGFR) and the T-cell surface antigen CD3. It is designed to stimulate T cells to attack EGFR-expressing tumor cells through dual binding, leading to immunostimulatory and antineoplastic effects. The drug exerts its action by engaging CD3 on T cells (stimulating their activity), antagonizing EGFR on tumor cells, and inducing antibody-dependent cell-mediated cytotoxicity (ADCC). Developed by Zhejiang Shimai Pharmaceutical, SMET12 is being investigated primarily for the treatment of advanced solid tumors—especially non-small cell lung cancer (NSCLC) with EGFR positivity—and other EGFR-positive neoplasms. Its highest reported clinical development phase is Phase 2 for NSCLC; it has also been studied in Phase 1 trials for solid tumors in China and the USA[1][2][3][4][5][7].

Other names

anti-EGFR/CD3 bispecific antibody SMET12